Clark Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Clark Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5	Closed	-$3.86K	–	632
2026 Q1	$3.86K	Hold	5	–	–	﹤0.01%	364
2025 Q4	$3.86K	Hold	5	–	–	﹤0.01%	363
2025 Q3	$3.86K	Buy	+5	New	+$2.83K	﹤0.01%	363
2025 Q2	–	Sell	-5	Closed	-$3.17K	–	619
2025 Q1	$3.17K	Hold	5	–	–	﹤0.01%	321
2024 Q4	$3.56K	Buy	+5	New	+$4.2K	﹤0.01%	283

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Clark Wealth Partners's REGN Position: Q2 2026 in Review

Clark Wealth Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 5 shares — an estimated $3.86K sold.

Clark Wealth Partners first reported a position in REGN in Q4 2024 and held it in 5 quarters. The position peaked at $3.86K in Q1 2026. 1,256 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Clark Wealth Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Clark Wealth Partners sold 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.86K.
Clark Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 5 quarters.
Clark Wealth Partners's Regeneron Pharmaceuticals position peaked at $3.86K in Q1 2026.
1,256 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Clark Wealth Partners's 13F filing for Q2 2026, filed 28 Jul 2026.